Skip to main content
. 2012 Sep;2(3):151–162. doi: 10.3978/j.issn.2223-4292.2012.08.04

Figure 4.

Figure 4

A. Representative in vivo MRI of islet transplantation showing MN-siCaspase-3-treated islets implanted under the left kidney (inset) and parental MN-treated islets implanted under the right kidney. The dark area outlined under both kidney capsules represents the labeled grafts (day 3 shown); B. Semiquantitative assessment of the relative changes in graft volumes revealed protective effect in MNsiCaspase-3-labeled grafts (*day 7, P<0.05; **day 14, P<0.05); C. Fluorescence microscopy revealed higher expression of insulin and lower expression of caspase-3 inMN-siCaspase-3-treated grafts compared with MN-labeled islet grafts on the 14th day after-transplantation (Tx) (green, insulin; red, cleaved caspase-3; blue, DAPI nuclear stain) (magnification bar =50 mm); D. TUNEL assay on insulin-stained sections confirmed lower apoptotic rate and higher insulin expression in islets treated with MN-siCaspase-3 compared with islets treated with MN on the 14th day post-Tx (red, insulin; green, TUNEL; blue, DAPI nuclear stain) (magnification bar =50 µm). Reproduced with permission from American Diabetes Association (60)